Providing a pathway to potent pain therapy without the risk of addiction and serious side effects.
Welcome to Phoenix PharmaLabs
Opioids are the most widely prescribed drugs for treatment of moderate to severe pain. They are also the most powerful analgesics for treatment of acute and chronic pain. However, their use is plagued by serious side effects, including abuse and addiction, severe withdrawal, constipation, respiratory depression, and death from overdose.
The CDC reports that over the past ten years mortality rates have declined for all serious medical conditions – except for death from prescription opioid abuse, which has risen dramatically since 1990. More than 2 million Americans are seriously addicted to opioids – and it is a devastating addiction. According to the CDC, “this is a major public health problem that is getting worse, and getting worse rapidly.”
Phoenix PharmaLabs, Inc. (PPL) is a privately held, pre-clinical stage drug development company focusing on the development and commercialization of improved non-addictive treatments for pain and new therapies for the treatment of opiate addiction.
We believe strongly in the value to humanity of a class of potent analgesics with the potential to relieve pain and suffering without the problems of abuse and addiction, serious side effects, and death from overdose.
PPL has designed a new class of opioid drugs with unique opiate receptor characteristics never before seen. Other opioids such as morphine, oxycodone, hydrocodone, etc. bind strongly to the mu receptor in the brain and then aggressively agonize that receptor. Mu produces euphoria which leads to abuse and addiction.
THEM
PPL’s drugs have high binding affinity at all three opiate receptors (mu, kappa and delta) and more balanced receptor activity than other opioids. This profile results in the first ever opiate analgesics that appear to be non-addicting and free of all significant dangerous side effects.
US
Extensive animal testing by prominent scientists at leading institutions has demonstrated that the company’s drugs offer robust pain relief (10 times stronger than morphine) without producing euphoria – which is what leads to abuse and addiction. They also demonstrate no dysphoria, no physical dependence, no withdrawal, no death from overdose (even at 350x the analgesic dosage), only moderate respiratory depression at 150x dosage, no constipation at 100x dose, and no other serious side effects. Also, they can sustain addicted primates without precipitating withdrawal and therefore offer very promising use for addiction therapy. The drugs are orally active and inexpensive to manufacture.
0X
10 TIMES MORE POTENT THAN MORPHINE
100
NO EUPHORIA OR DYSPHORIA
75
NO ADDICTION OR PHYSICAL DEPENDENCE
500
NO DEATH FROM OVERDOSE – (EVEN AT 350X DOSAGE)